← Leaderboards
Charlton B Strange
Columbia University Health Sciences
$2,966,083
Attributed
$5,932,165
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,932,165 · 2
By mechanism
UH3$4,258,583 · 1
UG3$1,673,582 · 1
Top collaborators
- Jeanine M D'Armiento6 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Rando L Allikmets$26,307,408
- Mary Sano$40,764,266
- Jeanine M D'armiento$14,757,679
- Scott A Small$25,024,830
- Melodie Rose Winawer$5,549,216
Others in their field
Other Emerging Leaders on “Dimensions”
- Christopher Bee · Suny At Stony Brook$41,239,084
- John Hobbs · Suny At Stony Brook$41,239,084
- Alan D. Palkowitz · Indiana University Indianapolis$17,686,071
- Crystal Mackall · Children'S Hosp Of Philadelphia$10,785,733
- Jorge Eduardo Chavarro · Harvard School Of Public Health$8,571,098
- John E Cazes · University Of Texas At Austin$7,350,000
Research focus
DimensionsDisease PhenotypeAirway RemodelingData SharingDisease HeterogeneityDisease OutcomeBiomedical InformaticsAlpha 1-AntitrypsinCharacteristicsBiologicalBiological MarkersDatabasesAlpha 1-Antitrypsin DeficiencyClinical DataClinical HeterogeneityClinically RelevantClinical ResearchClinical Research SiteClinical TrialsCohortCollaborationsContractsData AccessDisease Progression
Grant awards (6)
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease$808,451
UH3 · FY2025 · HL
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease$1,112,779
UH3 · FY2024 · HL
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease$1,159,459
UH3 · FY2023 · HL
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease$1,177,894
UH3 · FY2022 · HL
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease$933,377
UG3 · FY2021 · HL
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease$740,205
UG3 · FY2020 · HL